EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access

Low-Dose Planned Glucarpidase Allows Safe Outpatient High-Dose Methotrexate Treatment for CNS Lymphoma

Lauren R Schaff iD, Dean Carlow, Ryan Schofield, Venissala Wongchai iD, Juli Madzsar, Allison Hyde, Anne S Reiner iD, Katherine S Panageas, Lisa M DeAngelis, Ingo K Mellinghoff iD, Mina Lobbous iD, Louis B Nabors iD und 1 weitere

JCO Oncology Practice · 2024-10 · 20 (10) · 1384-1390

DOI: 10.1200/op.24.00080 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift JCO Oncology Practice, 2024-10. Verfasst von Lauren R Schaff und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Central Nervous System Neoplasms, gamma-Glutamyl Hydrolase, Lymphoma, Methotrexate. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE High-dose methotrexate (HD-MTX) is the backbone of curative therapy for CNS lymphoma. Because of toxicity, MTX is administered in the inpatient setting along with hyperhydration and monitoring until MTX clearance is documented (3-5 days). Frequent hospitalizations result in patient time away from work, home, and exposure to potential iatrogenic/nosocomial complications. Here, we aim to demonstrate feasibility of HD-MTX administration in the outpatient setting with low-dose glucarpidase facilitating clearance. METHODS This is a prospective nonrandomized study of outpatient HD-MTX followed by glucarpidase 2000u (ClinicalTrials.gov identifier: NCT03684980 ). Eligible patients had CNS lymphoma, creatinine

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Central Nervous System Neoplasmsgamma-Glutamyl HydrolaseLymphomaMethotrexateAdultAgedFemaleHumansMaleMiddle AgedAntimetabolites, AntineoplasticOutpatientsProspective StudiesRecombinant Proteins

Substanzen

Antimetabolites, Antineoplasticgamma-Glutamyl HydrolaseglucarpidaseMethotrexateRecombinant Proteins

Autor:innen und Institutionen

  • Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Neurology, Weill Cornell Medical College, New York, NY.
  • Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Cleveland Clinic Foundation, Neurological Institute, Rose Ella, Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland, OH.
  • Department of Neurology, University of Alabama at Birmingham, Birmingham, AL.

ORCID-Profile: Lauren R Schaff, Venissala Wongchai, Anne S Reiner, Ingo K Mellinghoff, Mina Lobbous, Louis B Nabors, Christian Grommes

Förderung

  • NCI NIH HHS
  • NINDS NIH HHS

Zitieren

APA

Schaff, L. R., Carlow, D., Schofield, R., Wongchai, V., Madzsar, J., Hyde, A., Reiner, A. S., Panageas, K. S., DeAngelis, L. M., Mellinghoff, I. K., Lobbous, M., Nabors, L. B., & Grommes, C. (2024). Low-Dose Planned Glucarpidase Allows Safe Outpatient High-Dose Methotrexate Treatment for CNS Lymphoma. JCO Oncology Practice, 20(10), 1384-1390. https://doi.org/10.1200/op.24.00080

Vancouver

Schaff LR, Carlow D, Schofield R, Wongchai V, Madzsar J, Hyde A, et al. Low-Dose Planned Glucarpidase Allows Safe Outpatient High-Dose Methotrexate Treatment for CNS Lymphoma. JCO Oncology Practice. 2024;20(10):1384-1390. doi:10.1200/op.24.00080

BibTeX
@article{Schaff2024,
  author = {Schaff, Lauren R and Carlow, Dean and Schofield, Ryan and Wongchai, Venissala and Madzsar, Juli and Hyde, Allison and Reiner, Anne S and Panageas, Katherine S and DeAngelis, Lisa M and Mellinghoff, Ingo K and Lobbous, Mina and Nabors, Louis B and Grommes, Christian},
  title = {Low-Dose Planned Glucarpidase Allows Safe Outpatient High-Dose Methotrexate Treatment for CNS Lymphoma},
  journal = {JCO Oncology Practice},
  year = {2024},
  volume = {20},
  number = {10},
  pages = {1384--1390},
  doi = {10.1200/op.24.00080}
}
Kostenlos starten →